ITW: This Swedish Biotech started the first Phase II in Bahrain Skip to content Reports Podcast Subscribe Log In Now covering the global biotech industry! Read More Topics CRISPR CAR-T Covid-19 Microbiome mRNA technology Gene therapy CRISPR CAR-T Covid-19 Microbiome mRNA technology Gene therapy Log In Now covering the global biotech industry! Read More Home » News and Trends » Interviewing the Swedish Biotech that started the first Phase II Trial in Bahrain Interviewing the Swedish Biotech that started the first Phase II Trial in Bahrain By Philip Hemme April 6, 2016 - 1 minute It’s the fist time I heard of a European Biotech company clinically co-operating with a country in the Arabic gulf… That’s why I was curious to interview Christina Herder, the CEO of the Stockholm-based Dilaforette, which launched a Phase II trial in co-operation with Bahrain and the rest of the Emirates. Dilaforette, as many Swedish Biotechs, started out from the Karolinska Institute and is now one of the portfolio companies of Karolinska Development (see the interview of the CIO here). The company is tackling Sickle Cell Disease with a small molecule drug (Sevuparin) and is currently undergoing a Phase II with Orphan drug designation. The interview is about this last development as well as the history of the company and how Herder perceives the Swedish Biotech ecosystem. Here’s a teaser: ‘the Swedish market is just too small, we have to go international‘. Content continues below Related Content Here’s the video shot at BIO-Europe Spring 2016 in Stockholm… Please accept preferences cookies to watch this video. Feature Image Credit: Philip Hemme and Christina Herder in Stockholm (available under CC 3.0 License by Labiotech.eu) Explore Related Topics: Sweden ADVERTISEMENT ADVERTISEMENT You might also be interested in the following: More from Labiotech News and Trends Grant awarded to help bring to market an innovative treatment for bone cancer News and Trends Knockback for drug to treat patients with relapsed or refractory multiple myeloma News and Trends Beyond Biotech podcast 15: Cullinan Oncology, Pleco Therapeutics, TikoMed Labiotech.eu is the leading digital media covering the global biotech industry. Over 150,000 monthly visitors use it to keep an eye on the business and innovations in biotechnology. Hope you’ll enjoy reading our stories! About us Inside Labiotech Join Us Advertise Contact Editorial Calendar Site Map Linkedin Twitter Youtube RSS Feed Made with in Berlin. Labiotech UG, All Rights Reserved - Imprint Privacy Policy Browse Topics Search for a topic, country or company name by using the search box Start typing... Search Popular topics: CRISPR mRNA technology CAR-T HIV Cell therapy Diabetes Microbiome Gene therapy Synthetic biology Log In Topics Gene Therapy CRISPR CAR-T Covid-19 Microbiome Diabetes Cancer Sections News and Trends In Depth Best in Biotech Opinion Interview Infographics Show All Topics For Members Expert Advice Reports Startup Scout More About us Inside Labiotech Join Us Advertise Contact Podcast Biotech Events ` }).join('') this.resultsNode.classList.remove('hidden') this.rootNode.setAttribute('aria-expanded', true) this.resultsCount = results.length this.shown = true this.onShow() } hideResults = () => { this.shown = false this.activeIndex = -1 this.resultsNode.innerHTML = '' this.resultsNode.classList.add('hidden') this.rootNode.setAttribute('aria-expanded', 'false') this.resultsCount = 0 this.inputNode.setAttribute('aria-activedescendant', '') this.onHide() } } const search = input => { if (input.length < 1) { return [] } return data.filter(item => item.toLowerCase().startsWith(input.toLowerCase())) } const autocomplete = new Autocomplete({ rootNode: document.querySelector('.autocomplete'), inputNode: document.querySelector('.autocomplete-input'), resultsNode: document.querySelector('.autocomplete-results'), searchFn: search, shouldAutoSelect: true })